- Home
- KMT vs KNSA Comparison
KMT vs KNSA Comparison
Compare KMT & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMT
- KNSA
- Stock Information
- Founded
- KMT 1938
- KNSA 2015
- Country
- KMT United States
- KNSA United Kingdom
- Employees
- KMT N/A
- KNSA N/A
- Industry
- KMT Industrial Machinery/Components
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- KMT Industrials
- KNSA Health Care
- Exchange
- KMT Nasdaq
- KNSA Nasdaq
- Market Cap
- KMT 2.0B
- KNSA 1.7B
- IPO Year
- KMT N/A
- KNSA 2018
- Fundamental
- Price
- KMT $28.45
- KNSA $21.29
- Analyst Decision
- KMT Hold
- KNSA Strong Buy
- Analyst Count
- KMT 5
- KNSA 5
- Target Price
- KMT $24.60
- KNSA $36.60
- AVG Volume (30 Days)
- KMT 1.2M
- KNSA 355.3K
- Earning Date
- KMT 11-06-2024
- KNSA 10-29-2024
- Dividend Yield
- KMT 2.81%
- KNSA N/A
- EPS Growth
- KMT N/A
- KNSA N/A
- EPS
- KMT 1.28
- KNSA N/A
- Revenue
- KMT $2,036,371,000.00
- KNSA $384,098,000.00
- Revenue This Year
- KMT $0.59
- KNSA $60.05
- Revenue Next Year
- KMT $2.57
- KNSA $36.32
- P/E Ratio
- KMT $22.23
- KNSA N/A
- Revenue Growth
- KMT N/A
- KNSA 54.41
- 52 Week Low
- KMT $22.50
- KNSA $15.51
- 52 Week High
- KMT $32.18
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- KMT 57.72
- KNSA 32.46
- Support Level
- KMT $24.96
- KNSA $22.62
- Resistance Level
- KMT $30.36
- KNSA $23.34
- Average True Range (ATR)
- KMT 1.05
- KNSA 1.18
- MACD
- KMT 0.17
- KNSA -0.19
- Stochastic Oscillator
- KMT 48.34
- KNSA 20.27
About KMT Kennametal Inc.
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.